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This monograph forms part of a series of disease monographs commissioned by the 
International Development Research Centre over the period Nov 2015 to April 2016 to 
inform funding priorities for the Livestock Vaccine Innovation Fund (LVIF). The LVIF is a 
seven-and-a-half year, CA$57 million partnership between the Bill & Melinda Gates 
Foundation, Global Affairs Canada and Canada’s International Development Research 
Centre. It focuses on those animal diseases posing the greatest risk to poor livestock 
keepers in Sub-Saharan Africa, South and Southeast Asia, targeting transboundary 
diseases to achieve lasting regional impact. 
 
The content presented here is as submitted by the consultant(s) involved and has been 
edited for appearance only. The views, information, or opinions expressed in this 
monograph are solely those of the individual consultant(s) involved and do not 
necessarily represent those of the Bill & Melinda Gates Foundation, Global Affairs Canada 
and International Development Research Centre, or any of their employees. Sections of 
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ASF  African swine fever 
ASForce Targeted research effort on African swine fever 
ASFV  African swine fever virus 
ASEAN  Association of South East Asian Nations 
AU-IBAR African Union InterAfrican Bureau For Animal Resources 
AU  African Union 
AusAID  Australian Agency for International Development  
BecA  Biosciences Eastern and Central Africa 
CSIRO  Commonwealth Scientific and Industrial Research Organization 
CVR  Central variable region 
DISC  Defective infectious single cycle 
dpi  Days post injection 
DRC  Democratic Republic of Congo 
ELISA  Enzyme-linked immunosorbent assay 
EURL-ASF European Union Reference Laboratory for African swine fever 
FAO  Food and Agriculture Organization of the United Nations 
FAT  Fluorescent antibody test 
GARA  Global African Swine Fever Research Alliance 
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IL  interleukins  
ILRI  International Livestock Research Institute 
kb  Kilo base pair 
MGF  Multigene family (e.g. 360 and 530 genes) 
nm  nanometers 
OIE  World Organization for Animal Health 
PCR  Polymerase chain reaction 
RT-PCR  Reverse transcription polymerase chain reaction 
SAARC  South Asia Association for Regional Cooperation 
TADs  Transboundary animal diseases 
TNF  Tissue necrosis factor 
USDA  United States Department of Agriculture 
VI  Virus Isolation 
VN  Virus Neutralization 
WAHID  Interface for the World Animal Health Information System 
WAHIS  World Animal Health Information System  
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ASFV is a large, enveloped, double-stranded DNA virus that replicates primarily in cells of the mononuclear 
phagocytic system. It is currently classified as the only member of a family called ASF–like viruses (Asfarviridae) 
[1].  ASFV is the only known DNA arbovirus [1][4].  There are currently 22 known genotypes of ASFV [4][6].  The viral 
genome is differentiated using the VP72 (p72) gene, the p54-gene and the B602L-gene.  ASFV is hardy and is 
able to survive for months or years in the environment, body fluids and in meat products.  ASFV is able to evade 
host defenses since it does not induce neutralizing antibodies in the host pig and it undergoes constant internal 
reassortment of the genome [4].  Differences in the serological responses of pigs have been related to the 
specific immunological characteristics of the local breeds of African pigs [10].   
The main strategy used by the virus to evade host defenses is to modulate the signaling pathway of infected 
macrophages in order to interfere with the expression of certain genes including those playing a role in the 
innate and acquired immunity [4] 
ASF occurs in four clinical forms in pigs including peracute, acute, subacute or chronic forms. The incubation 
period is between 5 and 21 days in susceptible pigs having direct contact with infected pigs, but it can be less 
than 5 days after exposure to ticks. Acute disease typically appears in 3 to 7 days [20].  The OIE advises that since 
“ASF cannot be differentiated from classical swine fever [3] by either clinical or post-mortem 
examination…laboratory tests are essential to distinguish between these diseases” [3].  Ornithodoros ticks and 
wild pig species act as reservoirs and biological vectors of ASFV and wild pigs remain asymptomatically infected.  
Infected pigs that survive infection can act as carriers for months. 
ASF was first described in Kenya in 1921 [11].  Since then, the virus has spread from wild African suidae 
(phacochoerus aethiopicus) to European domestic pigs brought to the African continent, causing 100% 
mortality. For decades it was confined to sub-Saharan Africa, until 1957 when it was detected in Lisbon, 
Portugal.   ASF remains enzootic in most countries of Sub-Saharan Africa including Madagascar. In 2007, it was 
introduced the Caucasus (Georgia, Azerbaijan, and Armenia) and later to Russia and the Ukraine [6].   There are 
four main transmission cycles and distinct regional patterns of ASFV in Africa including: 1) sylvatic cycle; 2) tick-
pig cycle; 3) domestic pig cycle; and 4) sylvatic to domestic pig cycle.  The basic reproductive rate (R0) for 
transmission is very high (3.24 in one case).  Risk factors for transmission include moving infected pigs, human 
movement by veterinary and paraveterinarians, feeding food waste of infected pigs and soft Ornithodoros ticks.   
The molecular epidemiology of ASFV in Africa provides evidence for the evolution of the virus over time as well 
as the epidemiological relationships among various disease outbreaks.  There is a difference in the epidemiology 
and great diversity between the two distinct regions of Africa, based on molecular epidemiology [4].  In the 
Eastern and Southern parts of Africa, from Uganda and Kenya to South Africa, there are high levels of genetic 
variation with 22 genotypes described thus far, including 13 and 14 genotypes in Eastern and Southern Africa, 
respectively. This high genetic diversity is related to the occurrence of a sylvatic cycle in most of these countries.  
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The Western and Central parts of Africa have one unique genotype suggesting the absence of a genetic diversity 
driven by a sylvatic cycle [4]. 
Reporting of ASFV incidence to the OIE peaked in 2002 and 2013 [26]. Rwanda, Malawi and Madagascar in East 
and Central Africa accounting for over half of the total number of outbreaks between 2000 and 2015. The 
greatest impact of ASFV has been on the poorer pig producers who lack basic biosecurity and financial resources 
to resume production in the absence of compensation schemes [13]. Implications of ASFV for food security in 
Africa are significant and ASFV remains an imposing and enormous risk to animal health and food security 
globally.  
The key challenges to developing a safe and effective vaccine for ASFV is due to the lack of understanding of the 
agent-host relationship including the following factors: 
• Mechanism of evading innate and acquired immune systems i.e. macrophages and monocytes and 
acquired immune systems including both humoral and cell-associated aspects; 
• The pig host does not develop neutralizing antibodies to ASFV; 
• Phenotypic differences among known genotypes; 
• Antigenic significance of approximately 150-165 genes of ASFV which can be used to target the 
development of safe and effective vaccines;  
• Dynamics of going internal re-assortment and presence of multigene families (MGF) which impede the 
ability to develop effective and safe vaccines; 
• Systematic coordination of basic research among international experts; 
• Mechanism for technology transfer from researchers to vaccine companies for commercial vaccine 
production; 
• Unique epidemiological drivers of ASFV of each area. 
 
The key gaps and solutions that need to be addressed prior to developing a potential vaccine: 
Short term 
• Facilitating coordination among international researchers to advance knowledge of the basic science of 
ASFV through a systematic approach for antigenic and immune related research; 
• Building local capacity for rapid detection including the development of a rapid pen side test for ASFV to 
support rapid diagnosis and permits differentiating infected from vaccinated animals (DIVA); 
• Conducting epidemiological and socioeconomic studies at the country and transboundary levels to 
understand the drivers and impacts of ASFV, including introduction, transmission and endemicity; 
• Leveraging efforts of research institutions through partnerships with the vaccine industry from the initial 
stages with potential to develop commercial products.  
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• Studies of infection dynamics based on direct challenge and indirect contact from infected animals; 
• Develop vaccine discovery models based on evidence from antigenic and immunological studies;  
• Promoting technology transfer to private vaccine companies to support a multivalent delivery platform. 
Long term 
Developing vaccines and vaccine delivery systems appropriate for each country and region based on molecular, 
epidemiological and socioeconomic parameters. 
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The ASFV is hardy and can survive for long periods of time under unfavourable conditions.  The OIE provides the 
following environmental information on resistance to physical and chemical inactivation of ASFV [5]. 
 
Virus structure 
ASFV is a large, enveloped, double-stranded DNA virus that replicates primarily in cells of the mononuclear phagocytic 
system. It is currently classified as the only member of a family called ASF–like viruses (Asfarviridae) [1].  ASFV is closely 
related to the family Poxviridae sharing the following traits:  1) viruses from both families replicate mainly in the 
cytoplasm of the infected cells; and 2) their genomes have terminal cross-links and inverted terminal repeats [2]. At 
least 28 structural proteins have been identified in intracellular inclusion bodies.  More than a hundred infectious 
proteins have been identified in infected porcine macrophages and at least 50 of them react with sera from infected 
or recovered pigs [3][4]. The virions contain the transcriptional machinery for the synthesis, capping and 
polyadenylation of early RNA.  The inner envelope protein p54 is required for membrane recruitment to initiate the 
replication process [5].  Standard nomenclature for ASFV isolates includes city or country of isolation and last two digits 
of year of isolation (e.g. Lisbon ’60, DR ’78). ASFV is the only known DNA arbovirus [4][6].  
 
Figure 1: ASFV structure [4] 
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• Temperature: Highly resistant to low temperatures. Heat inactivated by 56°C/70 minutes; 60°C/20 
minutes.  
• pH: Inactivated by pH <3.9 or >11.5 in serum-free medium. Serum increases the resistance of the virus, 
e.g. at pH 13.4 – resistance lasts up to 21 hours without serum, and 7 days with serum.  
• Chemicals/Disinfectants: Susceptible to ether and chloroform. Inactivated by 8/1000 sodium hydroxide 
(30minutes), hypochlorites – 2.3% chlorine (30 minutes), 3/1000 formalin (30 minutes), 3% ortho-
phenylphenol (30 minutes) and iodine compounds.  
• Survival: ASFV remains viable for long periods in blood, faeces and tissues; especially infected, uncooked 
or undercooked pork products. Can multiply in vectors (Ornithodoros sp.).  
The molecular composition of ASFV is characterized by sequencing the C- terminal end of VP72 gene, which 
permits the differentiation of 22 distinct genotypes [4].  The full genome sequence of the p54-gene has been 
confirmed as a valuable additional genotyping method for molecular epidemiological studies. Enhanced 
discrimination is obtained by analysis of the CVR within the B602L-gene, described as the most variable locus to 
identify virus subgroups within several of the 22 genotypes. Figure 2 illustrates the phylogenetic relationships of 
67 European, American, and West and East ASFV isolates.  Analysis of these 67 isolates reveals that West African 
and European ASFV isolates are classified within Genotype I according to partial sequencing of p72 and these 
isolates were further classified into four major sub-types on the basis of their p54 sequences [7].  
In summary, the viral genomic differentiation is possible using the following methods: 
• The VP72 (p72) gene; 
• The p54-gene sequencing confirms the separation of viruses into three additional clusters (V, X, and XX) 
that were homogeneous using p72 [7][8];   
• The B602L variable region differentiates multiple sub-groups region.  Using isolates obtained over a 40-
year period following passage in either pig macrophages or O. erraticus ticks, isolates, which were 
previously grouped together, could be further differentiated [9].   
ASFV remains one of the most challenging animal viruses because the virus does not induce neutralizing 
antibodies and its genome undergoes a highly variable and constant internal reassortment [4].  For these and 
other reasons, ASFV is endemically established in Africa.   Serological tests are recommended where the disease 
is endemic or where a primary outbreak is caused by a strain of low virulence or avirulent [4].  One comparative 
serological study concluded that the challenge of serological diagnosis is not attributable to antigenic 
polymorphism, but rather may be related to the specific immunological characteristics of the local breeds of 





African Swine Fever | Monograph 08 










Figure 2: Genetic relationships of 67 European, American, and West and East ASFV isolates 
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Table 1 summarizes key epidemiological features of ASFV to be further explained in greater detail under agent, 
host and environmental headings below [6]. 
 
Table 1: Key epidemiological features of ASF  
 
Reservoirs inapparently infected 
from Africa 
• African wild swine (warthogs, (Phacochoerus aethiopicus)) Bush pigs 
(Potamochoerus sp.)  
• Giant forest hogs (Hylochoerus meinertzhageni) 
Hosts demonstrating symptoms • Domestic pigs (Sus domesticus),  
• European wild boar  
• American wild pigs  
Host and vector • Ticks of the genus Ornithodoros are considered natural arthropod host 
Transmission • Direct transmission between sick and healthy animals 
• Indirect transmission by feeding garbage containing infected meat (ASFV 
can remain infectious for 3–6 months) 
• Biological vectors – soft ticks of the genus Ornithodoros 
• Fomites (premises, vehicles, implements, clothes) 
• Within tick vector: transstadial, transovarial, and sexual transmission 
Virus sources • Blood, tissues, secretions and excretions from sick and dead animals 
 
 
Montgomery first described the disease in Kenya in 1921 [11].  The virus spread from wild African suidae 
(phacochoerus aethiopicus) to European domestic pigs more recently brought to the African continent, resulting 
in 100% mortality. For decades ASFV was confined to sub-Saharan Africa, until 1957 when it was detected in 
Lisbon, Portugal having spread from Angola, in the form of a peracute disease with high mortality.  Figures 3, 4 
and 5 depict the spatial distribution of ASFV during the time periods 1957-1967, 1997-2002 and 1998-2010 [11]. 
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Figure 5: Spatial distribution of ASFV from 1997-2002 
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ASF remains endemic in most countries of Sub-Saharan Africa including Madagascar. In Europe, it has been 
reported and successfully eradicated from the Iberian Peninsula but continues to be found in Sardinia, Italy. In 
the 1970s, ASFV was present in the Caribbean (Haiti and the Dominican Republic) and one country in South 
America (Brazil) but was successfully eradicated. Most recently, it has appeared in the Caucasus (Georgia, 
Azerbaijan, and Armenia) and Russia [6]. 
The four main transmission cycles and distinct regional patterns of ASFV with reference to Africa are 
summarized in Table 2 and Table 3 below [12][13][14]. 
1.  Sylvatic cycle 
The sylvatic cycle has been documented in southern and Eastern Africa, where it involves both warthogs and 
ticks of the Ornithodorous moubata group. Young suckling warthogs are infected in burrows infested with soft 
ticks. A short period of viraemia follows, enabling transmission of ASFV to naïve ticks during blood meals. 
Warthogs remain asymptomatically infected for life, but due to the absence of horizontal and vertical 
transmission among warthogs, further transmission is dependent on O. moubata ticks.  However, the presence 
of both warthogs and ticks in a region does not necessarily imply the existence of a sylvatic cycle. So far, a 
sylvatic cycle has not been documented in West Africa since warthogs or soft ticks are rarely infected. Studies in 
Eastern and Southern Africa showed that infection rates of free- living warthogs were rarely below 80 per cent 
in areas where the tick vector was present. 
2.   Tick-pig cycle 
Ornithodorous ticks commonly feed on domestic pigs and can be involved in the transmission and long-term 
maintenance of ASFV.  In Madagascar, ASFV was isolated from ticks found on a farm where no pig had been 
introduced for at least four years.  However, the risk of ASFV infection decreases when tick populations become 
extinct following the absence of hosts over an extended period of time.  Experimental transmission to pigs was 
demonstrated from ticks that tested positive within 380 days following an outbreak.  
 3.  Domestic pig cycle 
Once introduced into domestic pig populations, ASFV is transmitted through direct contact and by fomites.  As 
previously noted, ASFV persists in blood and tissues for months so many animals can become infected at one 
location. Transmission through direct contact between domestic pigs can occur for up to 30 days after infection, 
or for eight weeks in the case of contact with blood as occurs during fighting or mating. Both pig trading and pig 
movement may be accelerated during an outbreak and the lack of biosecurity practices all contribute to the 
local spread of ASF in endemic areas.  
4.  Transmission from sylvatic to domestic cycles  
Possible mechanisms for transmission of ASFV to occur in this way include the following: 
• Soft tick vectors are the most likely means of transmission from African wild pigs to domestic pigs;  
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• Interbreeding between wild and domestic pigs may occur; 
• Feeding infected wild pig meat to domestic pigs may also occur. 
Factors found to increase the risk of outbreaks in domestic pigs are summarized in Table 2. 
 
Barongo et al. estimated the basic reproductive rate (R0) for ASF virus in smallholder, free-range pig production 
system in Gulu, Uganda as 3.24 outbreaks generated per infected source [15].   
 
 
Table 2: Risk factors associated with occurrence of ASFV with references  
 
Risk Factor Reference 
Pigs are unconfined and free-ranging  Allaway et al., 1995; Edelsten and Chinombo, 1995; 
248 Mannelli et al., 1997 
Previous occurrence of the disease on the farm Randriamparany et al., 2005 
Presence of an infected pig farm in the neighbourhood or of 
an abattoir in the community and  
Fasina et al., 2012 
Visits by paraveterinarians and veterinarians  Fasina et al., 2012 
Density of the road network, of water bodies and of the 
domestic swine population  
Gulenkin et al., 2011 
Spread model shows the movement of infected animals to 
be the most important factor for ASF transmission 
Olugasa and Ijagbone, 2007 
Emergency sale of asymptomatic pigs  Babalobi et al., 2007; Costard et al., 2009b; Fasina et 
al., 2010; Randriamparany et al., 2005 Costard et al., 
2012b 
Feeding of bush pig meat to domestic pigs.  Sánchez-Vizcaíno et al., 2009 
Rapid transmission and spread. High basic reproductive rate 
(R0) for ASF virus in smallholder, free-range pig production 
systems  
Barongo et al., 2015 
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Agent Factors   
The stability of ASFV is described below for different isolates and matrices [4].  
1. Pig feces:  
• 60 to 100 days.  
2. Laboratory medium or serum:  
• 6 years at 5°C in the dark;  
• 18 months in serum at room temperature;  
• up to one month at 37°C;  
• 3.5 hours at 56°C (note that serum is normally safely sterilized after 30 minutes at 60°C). 
3. Pork products:  
• 140 days in Iberian and white Serrano hams;  
• 399 days in Parma ham;  
• 112 days in Iberian pork loins. 
Like other large DNA viruses, ASFV has developed a large range of defense mechanisms to escape from the 
immune host responses. In vivo, the virus replicates in macrophages, which are part of the innate immune 
system responsible for: 1) capturing and presentation of antigens to lymphocytes (acquired immune 
mechanism) of cell mediated immune systems;  2) engulfing and ingesting microbes independently or antibody 
coated (opsonized) pathogens and 3) secreting pro-inflammatory cytokines. ASF virus can persist in the natural 
hosts and in domestic pigs, which recover from infection, indicating that ASFV can evade host defense systems 
[4].  The main strategy used by the virus to evade host defenses is to modulate the signaling pathway of infected 
macrophages in order to interfere with the expression of certain genes including those playing a role in the 
innate and acquired immunity [4].  
Using sera of infected animals it is possible to distinguish ASFV isolates based on the inhibition of the virus 
haemadsorbtion.  Based on this phenomenon, pigs surviving infection or pigs infected with low virulent isolates 
generate antibodies that inhibit virus-specific haemadsorbtion have been divided into three groups, namely A, B, 
and C.  However this categorization is not able to fully distinguish ASFV isolates [4].  
Variability studies show that viral DNA is made up of a more preserved central area (B602L region of the ASFV 
genome) and two variable areas at the ends of the molecule, where diversity among isolates is greatest. As 
previously noted, different ASFV isolates have been classified in groups based on the relatively conserved central 
area [15].   
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The molecular epidemiology of ASFV in Africa provides evidence for the evolution of the virus over time as well 
as the epidemiological relationships among disease outbreaks. 
Figure 6 presents the geographic distribution and phylogram of ASFV genotypes in Africa recently summarized 





Figure 6: Geographic distribution and phylogram of ASF genotypes in Africa 
 
The differences in genome size and enzymatic restriction profile among isolates show a high level of antigenic 
variability due to a change in the number of genes in a MGF, resulting in a large diversity between isolates 
through homologous gene recombination. A reduction in the number of MGF genes seems to be associated with 
lower virus virulence.  Comparison of the ASFV genomes showed that 85% of the encoded proteins were 
identical between viruses, the more variable ones belonging to the MGF [4].  
 
In Africa, attention is focused on the evolution of the circulating strains, from the molecular and the biological 
point of view as a means of explaining mechanisms of virus maintenance. [4].  
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On the African continent, ASFV has been endemic and circulating for a long period of time with minimal 
intervention.  As a result, there is great diversity within two distinct regions of Africa based on molecular 
epidemiology [4]: 
• The Western and Central parts of Africa, from Namibia to DCR and to Senegal, where the unique 
genotype I is circulating. Its high homogeneity does not reveal the exact origin of the virus exported 
from Eastern Africa to Western Africa and Europe or to explain the difference between outbreaks 
occurring as early as 1959 and those as recently as 2000 in West Africa.  However, this homogeneity 
supports studies demonstrating the absence of a sylvatic cycle in West Africa in contrast to the Eastern 
and Southern African countries.  
• Isolates from the Eastern and Southern parts of Africa, demonstrate high levels of genetic variations. A 
total of 22 genotypes are currently described, with 13 and 14 genotypes in Eastern and Southern Africa, 
respectively. This high genetic diversity is related to the presence of a sylvatic cycle, which plays a crucial 
part in the transmission of the disease. Zambia currently has seven (7) genotypes, South Africa has six 
(6), Mozambique has four (4), Malawi and Tanzania each with three (3), and Kenya and Uganda each 
with two (2). Some genotypes (VIII and XIX) are extremely homogeneous and seem to be associated to 
pig-restricted cycles or pig-domestic tick exchanges.  Other genotypes (V, X, XI, XII, XIII, XIV) were either 
isolated from domestic pigs, wild ticks or warthogs in both sylvatic and domestic cycles. Some genotypes 
are more country specific (V, VI, IX, XI, XIII, XIV, XV and XVI) while others (I, II, V, VIII, X and XII) are not 
restricted by national boundaries.  
Using p72 and other molecular markers such as 9RL, molecular genetics can be to distinguish viruses causing 
outbreaks that are geographically or temporally related. Several case studies are presented [4]: 
• ASF outbreaks occurring in Uganda in 1995 caused by two different viruses are associated with the 1984 
and 1990 outbreaks in Burundi. 
• Outbreaks occurring in South Africa in 1995 and 1996 are believed to represent two unrelated epizootics 
including four genotypically unrelated viruses.   These results contrast with the recovery of the same 
unique genotype from the 1987, 1992 and 1996 outbreaks in South Africa, indicating endemicity of this 
virus.  
• ASF viruses recovered from the single outbreak focus in 1998 in Mozambique belonged to the two 
unrelated genotypes II and VIII.  The same genotypes occurred in two different regions of Mozambique 
in 1994 (Bastos et al. 2004). Prolonged presence of both genotypes has been supported by the recovery 
of a genotype II virus from outbreaks in Nampula and Cabo Delgado provinces of Mozambique between 
2001 and 2003, and a genotype VIII virus from an outbreak in Zambézia Province in 2001.  
• The parallel identification of the genotype II in Madagascar indicates that Mozambique was the most 
likely source of infection for the 1998 introduction of ASFV into Madagascar.  
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ASF is a very complex viral disease that affects only wild and domestic porcine species [10].   Pathogenesis 
mechanisms of infection by ASFV of different virulence are not yet well understood and pig host immune 
responses to ASFV infection are complex. Antibodies per se do not appear to protect against infection and more 
recent studies emphasize innate cellular and cellular based immune mechanisms as relevant for animal survival.  
ASF can be transmitted directly from diseased or carrier pigs to healthy swine though direct or indirect contact 
or indirectly through fomites, ingestion of raw infected pork or pork products, or by biological vectors such as 
Ornithodoros ticks [4].    
It is essential to consider the specific epidemiological host factors for each area as unique.  For example, the 
maintenance of the virus in domestic pigs are more important than the association with warthogs as a cause of 
outbreaks of ASF in most parts of Mozambique [16].  The wild suids such as warthogs in Eastern Africa play a large 
role in eastern Africa, whereas this reservoir host does not play a significant role in western Africa [17]. 
Maintenance of ASFV in domestic pig populations is also specific in each area and for each outbreak. 
Interestingly, European wild boars are usually more resistant than domestic pigs to ASFV infection, although 
they present a similar pathological and epidemiological pattern [17]. 
Infected pigs shed the virus during the incubation period (15-21 days) and for up to 48 hours before the onset of 
clinical signs of disease.  During the clinical stage of disease, higher levels of virus are present in blood, 
secretions and excretions. Pigs that recover may shed virus for up to a month after the disappearance of clinical 
signs [18]. 
The co-existence of different ASFV genotypes in warthog burrow-associated ticks and adult wild warthogs was 
demonstrated in one endemically infected area in East Africa. The data from this and earlier studies suggest 
transfer of viruses of at least two different p72 genotypes, from wild to domestic pigs in East Africa [19].  
 
Environmental Factors 
Understanding the ecology of the interface between natural and farm ecosystems, ASF hosts, carriers and 
vectors is critical to the epidemiology and risk factors for ASFV in different regions of the world.  ASFV replicates 
in swine and in soft ticks of the genus Ornithodoros. However, there are different epidemiological cycles or 
scenarios depending on the specific circumstances in each geographical area regarding virus strain, host 
susceptibility, and biological vector presence and/or vector interaction with susceptible hosts. Pig production 
and management systems strongly influence the epidemiology of the disease as well as the prevention and 
control efforts required.  The following examples are presented: 
• Eastern Africa: ASFV is maintained mainly in a sylvatic cycle involving O. moubata vectors and warthogs, 
complicating control efforts;  
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• Western Africa: transmission between domestic pigs due to uncontrolled movement; Iberian Peninsula: 
O. erraticus was mainly associated to domestic rather than wild suids habitats; effectively control by 
replacing the old pigsties by modern structures;  
• Sardinia, Italy and some African countries: the disease is maintained by free range/backyard production 
systems where recovered pigs act as carriers;  
• Caucasus: contacts between diseased wild boar and free ranging pigs play an important role in the 
spread of ASF [4].  
 
A more detailed tabular summary of evidence for ASFV occurrence in East and West African ecological systems is 
presented in Table 3 [12]. 
Table 3: Evidence of ASFV occurrence in East and West African environments [12] 
 
Regional Evidence Reference 
East and South Africa 
Sylvatic cycles with sporadic emergence in domestic pigs have been 
described in these regions; in Kenya and South Africa, Genotypes I, X and XX 
isolates were recovered from warthogs and ticks found nearby to affected 
pig farms  
Heuschele and Coggins, 1965b; Pini 
and 394 Hurter, 1975 
In Malawi, the existence of both tick-pig and domestic cycles has been 
demonstrated; in the endemic central region of the country, ASF was shown 
to affect farms with soft ticks in areas without warthogs  
Haresnape, 1984; Haresnape et al., 
1985, 1987, 1988; Haresnape and 
Mamu, 1986; Haresnape and 
Wilkinson, 1989 
In Zambia, the studies suggest the existence of a domestic cycle, with 
sylvatic cycles restricted to national parks and their adjacent areas.  
Wilkinson et al. 1988 and Samui et al. 
1996 
In Mozambique, ASF is endemic in regions close to Malawi and Zambia but 
outbreaks are reported throughout the country. A sylvatic cycle may occur 
in some national parks and be the cause for important pig losses in the 
surrounding areas  
Penrith et al., 2007 
West Africa 
In West Africa, the domestic cycle is the only one involved in the persistence 
of ASFV 
Sanchez-Vizcaino et al., 2009 
In Senegal, epidemiological studies and molecular typing suggest that 
warthogs and O. sonrai ticks are unlikely to be involved in transmission of 
Bastos 423 et al., 2003; Jori et al., 2007; 
Vial et al., 2007; Etter et al., 2011 
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ASF can be observed in pigs in four clinical forms:  1) peracute; 2) acute; 3) subacute; or 4) chronic disease. The 
incubation period is 5 to 21 days after direct contact with infected pigs, but it can be less than 5 days after 
exposure to ticks. Acute disease typically appears in 3 to 7 days [20]. Table 4 summarizes the clinical features of 
four clinical forms of ASFV based on experimental evidence in pigs [4][21].  Wild African pigs are very resistant to 
infection and when infected, they are asymptomatic. 
 
the disease. High serological prevalence was found in farms where animals 
did not exhibit clinical signs 
Madagascar 
Recent studies suggest that ASF is restricted to the domestic pig population, 
with seasonal peaks of ASF and mostly unspecific symptoms reported by 
farmers. An abattoir survey conducted in 2006 found up to a quarter of 
slaughtered pigs infected with ASFV  
Costard et al., 2009b 
Both bush pigs and O. moubata ticks are present on the island, but no 
evidence of bush pig-ASFV or bush pig-tick was detected. Molecular 
epidemiology supports these findings, with all circulating viruses belonging 
to Genotype II  
Roger et al., 2001; Jori et al., 2007; 
Ravaomanana et al., 2010, 2011; 
Bastos et al., 2003 
 
 
Table 4: Clinical manifestations of ASFV in the pig host based on experimental challenge model [4][21] 
http://sanidadanimal.info/cursos/asf/caps/cap6.html 
 
Death (dpi) Clinical Signs 
Peracute, high virulence 
80-100% 7 dpi 
or less 
• Sudden death 
Acute, high virulence 
80-100% • Fever 40-42 OC 
• Recumbent, anorexia, huddling, cyanosis of ears; 
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• Final stages: rapid laboured breathing; serous or seromucous nasal secretions; nasal 
haemorrhaging, constipation and vomiting, and to a lesser extent, diarrhoea; melena; 
• Exanthemas (pinkish almost purple skin due to intense hyperaemia) or cyanotic foci, which 
appear as irregular purple-coloured marks on the skin of the extremities, ears, chest, abdomen 
and perineum; 
• Abortion in gestating females; 
• Death within 6-13 days, or as late as 20 days; survivors are carriers for life In domestic swine, 
the mortality rate often approaches 100%. 




• Clinical signs develop more slowly and the disease produces temporary thrombocytopenia 
resulting in death 
• Haematomas and necrotic areas, though these lesions 
• Irregular recurring fever for up one month, followed in most cases by recovery; 
• Duration of illness up to 30 - 45 days; 
• Anorexia and loss of condition; 
• Coughing and dyspnoea; 
• Exercise intolerance and death due to cardiac pathology; 
• Abortion in pregnant sows;  
• Mortality rate is lower but varies widely. 
Chronic, mild virulence 
2-10% 
mortality 
• Variety of clinical signs which are mainly the result of secondary bacterial complications; 
• Abortions; 
• Necrosis of the skin and buccal cavity, as well as arthritis, lameness; 
• Weight loss, growth retardation of growing pigs which have a long hairy coat, irregular peaks of 
temperature, respiratory signs 
• Lameness caused by arthritis that due to necrosis of cartilage; 
• Animals are vulnerable to secondary infections and pneumonia over 2-5 months 
• Low mortality (less than 30%) 
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The diagnosis of ASFV utilizes VI and serological evidence of exposure, depending on the laboratory capacity 
available [3].  The following factors should be considered [3][21]: 
• Early detection is critical since there is currently no effective vaccine; 
• There are no neutralizing antibodies, there are no multiple serotypes, only genotypes; 
• Viraemia begins during the incubation period and can be prolonged; 
• Persistence of antibodies for months or years; 
• Infection results in antigen-antibody complexes related to vascular endothelial damage. 
The following tissues from filter organs of dead animals are to collected and preserved under cold chain 
conditions for diagnosis: lymph nodes; spleen; kidney; lung; as well as whole blood and serum [3][21]. 
 
Differential Diagnosis 
Table 5 presents a summary for the main differential diagnoses of ASF [21]. 
The OIE advises that since “ASF cannot be differentiated from classical swine fever (hog cholera; Classical Swine 
Fever) by either clinical or post-mortem examination, and both diseases should be considered in the differential 
diagnosis of any acute febrile haemorrhagic syndrome of pigs. Bacterial septicaemias may also be confused with 
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Pig macrophages are the main targets for viral infection. Deeper characterization of viral interactions with these 
cells, and with the domestic pig as a natural host, using viral isolates characterized at genome level (naturally 
obtained or experimentally manipulated) is required in order to gain new insights to facilitate the manipulation 
of pig immune responses This will enable induction of protective immune responses and contribute to the 
development of effective vaccines [4].    
The virus interaction with the macrophage and monocytic cells in the immune system produce characteristic 
haemadsorption before the infected cell is destroyed. Viral replication has also been observed in endothelial 
cells, hepatocytes, renal tubular epithelial cells and neutrophils. However, Infection has not been described in T 
or B lymphocytes [20]. The gross pathological lesions of ASFV are summarized in Table 6 [21]. 
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In developing countries, identification of the agent is possible in a few reference laboratories so sample must 
always be sent for confirmation to these recognized laboratories. The OIE identifies the following diagnostic 
techniques when ASFV is suspected [3]: 
1. Identification of the agent. 
a. Haemadsorption test: The haemadsorption (HAD) test (Malmquist & Hay, 1960) is based on the fact 
that pig erythrocytes will adhere to the surface of pig monocyte or macrophage cells infected with 
ASFV and that most virus isolates produce this phenomenon of haemadsorption. A positive result in 
the HAD test is definitive for ASF diagnosis. Alternatively, the Haemadsorption ‘autorosette’ test 
with peripheral blood leukocytes from infected pigs, when obtaining timely results is of the essence. 
b. Antigen detection by FAT: The FAT (Bool et al., 1969) can be used as an additional method to detect 
antigen in tissues of suspect pigs in the field or those inoculated at the laboratory. Positive FAT plus 
clinical signs and appropriate lesions can provide a presumptive diagnosis of ASF. It can also be used 
to detect ASFV antigen in leukocyte cultures in which no HAD is observed and can thus identify non-
haemadsorbing strains of virus.  
c. Detection of virus genome by the PCR: PCR techniques have been developed, using primers from a 
highly conserved region of the genome, to detect and identify a wide range of isolates belonging to 
Table 6: Characteristic pathological lesions of ASFV 
 
Form Characteristic Lesions 
Peracute • Severe pulmonary oedema, xanthema; 
• Hyperaemic splenomegaly; 
• Haemorrhage: lymphatic ganglia, kidneys, bladder, pharynx, larynx, endocardium, pericardium; 
• Hydropericardium. 
Acute  
Subacute • Haemorrhage and necrosis: lung, kidneys, gall bladder, pharynx, larynx, endocardium, pericardium, 
submandibular and retropharyngeal lymph nodes, mediastinal, inguinal and mesenteric ganglia, 
serous layer of the small and large intestine, fundic mucosa of the stomach and skeletal muscle; 
• Fibrinous pericarditis. 
Chronic • Haemorrhage: renal and gastro-hepatic lymph ganglia and kidneys. 
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all the known virus genotypes, including both non-haemadsorbing viruses and isolates of low 
virulence. Two validated PCR procedures are described:   
i. PCR amplification by conventional PCR (Agüero et al., 2003)  
ii. PCR Procedure: TaqMan® PCR protocol (King et al., 2003)  
2. Serological tests  
Antibodies persist in recovered pigs for long periods after infection, sometimes for life,  and a number of tests 
are available for detecting these antibodies.  
a. ELISA (the prescribed test for international trade): The ELISA (Pastor et al., 1990) is a direct test that 
can detect antibodies to ASFV in pigs that have been infected by viruses of low or moderate 
virulence.  
b.  Indirect FAT:  This test (Pan et al., 1974) should be used as a confirmatory test for sera from areas 
that are free from ASF and are positive in the ELISA, and for sera from endemic areas that give an 
inconclusive result in the ELISA.  
c. Immunoblotting test (Escribano et al., 1990; Pastor et al., 1989): This test should be used as an 
alternative to the IFA test to confirm equivocal results with individual sera. The immunoblotting test 
is very specific and enables easier and more objective interpretation of the results and a better 




ASFV is not considered to be a zoonosis.  However, viral sequences related to the afarvirus family but highly 
divergent from ASFV have been reported in human serum and sewage [23]. Detection of these sequences 
suggests that greater genetic diversity than previously though may exist among asfarviruses and this raises the 
possibility that human infection by asfarviruses may exist.  
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European countries ASFV outbreaks include: France (1964), Italy (1967, 1969, and 1993), Malta (1978), Belgium 
(1985), and Netherlands (1986), Portugal (1999. ASF remains endemic on the island of Sardinia, Italy since 1978 
but it has been eradicated in the other countries.  
 
Countries in the American continents affected by ASFV include: Cuba (1971, 1980), Brazil (1978), Dominican 
Republic (1978) and Haiti (1979). ASF was successfully eradicated in all countries. 
 
In 2007, ASFV was reported on the European continent, in the Caucasus region.  Outbreaks were detected near 
the port of Poti, Georgia, likely related to infected pork meat that was brought by international ships. 
Subsequently, ASF spread to the neighbouring countries of Armenia, Azerbaijan and the Russian Federation, 
causing huge economic loses. 
 
Figure 7 presents the global distribution of ASFV in 2015 [24]. Figure 8 presents a regional map of distribution of 
ASFV events in Africa during 2011 [25].  
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= Present, no further details      = Widespread       = Localised 
= Confined and subject to quarantine      = Occasional or few reports 
= Evidence of pathogen       = Last reported      = Presence unconfirmed 
Figure 8: Regional map showing the distribution of ASFV events in Africa during 2011 [25] 
 
African Swine Fever | Monograph 08 








Table 7: Incidence of ASF in 20 Selected Countries, 2000-2015 [26] 
 
Region/Country 
Reported Incidence ASFV [26] http://www.oie.int/wahis_2/public/wahid.php/Diseaseinformation/statusdetail# (Accessed 20 October 
2015) 
 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Sub Saharan Africa                 
Burkina Faso 0 0 0 1 1 …+ 0 2 5 34 33 27 52 37 7 … 
Ethiopia 0 0 0 0 0 … … … … … … ? ? … … … 
Ivory Coast 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 … 
Kenya 0 3 0 0 0 0 0? 7 0 0 2 4 …+ 0 0 1 
Madagascar 33 … 72 41 22 17 7 ...+ ...+ ...+ 7 4 3 7 7 … 
Malawi 23 41 16 9 26 24+ 17 21 14+ 6 35 42 19 33 … … 
Mali 0 0 0 0 0 0 0 … … … … … … … … … 
Mozambique 8 8 5 6 15 16 13 11 12 7 11 12 6 9 4 … 
Rwanda … … 51 99 … … 64 29 26 6+ 53 50+() …+() 96 … … 
Senegal 0 4 3 3 1 2 2 6 0 1 0 0 0 0 0 0 
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South Africa 0 2 3 2 2 1 1 1 2 …+() 0 1+? 18 ?+ 3 … 
Tanzania 0 15 1 16 4 1+? 0 0 4 ...+ 1…+ 14 ()+ 19 7 4 
Uganda 32 52 57 28 24 3 …+ 3...+ 2…+ ...+ 1…+ 10 … 1 …+ … 
Zambia 1 5 7 0 5 … 3+() 4 13 19 6 ()+ 1 23 12 … 
South Asia                 
Bangladesh 0 0 0 0 0 0 0 0 0 0 0 0 0 … … … 
India 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 … 
Nepal 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 … 
Southeast Asia                 
Indonesia 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 … 
Myanmar 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 … 
Vietnam 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
 
 
WAHIS Codes 2005-2015 
... No information available for this disease 
0 Disease absent 
African Swine Fever | Monograph 08 










? Disease suspected 
? + Infection/infestation 
...+ Disease present but without quantitative data  
+ Disease present with quantitative data but with an unknown number of outbreaks 
+() Disease limited to one or more zones 
 
HandiStatus II Codes 2000-2004: 
... No information available 
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Total Number of Reported ASFV Events Reported 






















Total Number of ASFV Events by Year, 2000-2015
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“During 2011, ASF outbreaks were reported to AU-IBAR by 22 countries with a total of 471 affected 
epidemiological units involving 144,950 cases, 135,712 deaths and a case fatality rate of 93.6%. Significantly, the 
DCR registered the highest number of outbreaks (84) accounting for about 17.8 % of the reported outbreaks and 
79.4% of mortalities (AU-IBAR, 2011)” [25].  
Table 8 presents a summary of the number of ASFV outbreaks from Africa reported in 2011 [25]. Figure 11 depicts 
the increasing historical temporal distribution of outbreaks in East, South, Central and West Africa until 2011 [27]. 
Table 8: Characteristic pathological lesions of ASFV 
 
Country Outbreaks Cases Deaths Slaughtered Destroyed 
Benin 25 1426 815 536 52 
Burkina Faso 26 1518 1134 0 0 
Cameroon 4 146 89 0 NS 
Central African 
Republic 
17 993 742 0 0 
Chad 7 189 126 59 54 
Congo Brazzaville 1 2 2 0 0 
DCR 84 105,614 105,614 9691 49 
Ethiopia 7 28 19 0 NS 
Gambia 5 198 198 0 0 
Ghana 7 567 510 152 25 
Kenya 6 57 53 0 NS 
Liberia 1 12 4 8 0 
Madagascar 19 540 540 NS 91 
Malawi 36 19,755 18,956 114 19 
Mozambique 16 591 380 0 316 
Nigeria 1 1 70 0 0 
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Rwanda 60 677 600 2054 647 
South Africa 1 NS NS NS NS 
Tanzania 7 2063 1334 NS NS 
Togo 80 2363 1151 235 40 
Uganda 56 7788 3763 1584 99 
Zambia 5 422 212 NS NS 






Figure 11: Total Number of Reported ASFV Events Reported year, 2000-2015 
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Table 9: Prevalence estimates of ASFV in selected African countries 
 
Region/Country Apparent Prevalence (CI) Study Design Time Period Reference 
Sub Saharan Africa 
    
Burkina Faso 
    
Ethiopia 
    
Ivory Coast 
    
Kenya Analysis of blood and serum samples using a 
PCR assay demonstrated an average animal 
level positivity to ASFV of 28% in two 
independent samplings in South-western 
Kenya and 0% PCR positivity in Central 
Kenya. 
Prospective cross-sectional study of 
seroprevalence and virus prevalence in 
two pig producing regions of Kenya. 
2008-2009 Okoth et al, 2012 
Madagascar Prevalence estimates provided by the 
abattoir survey varied between areas: 1% in 
Ambatondrazaka, 10% in Marovoay and 
24% in Arivonimamo areas of Madagascar 
Prospective cross-section virus prevalence 
survey 
2006 Costard et al., 2009 
Malawi 
    
Mali 
    
African Swine Fever | Monograph 08 






Mozambique The seroprevalence to ASFV was 12.6% on 
farms and 9.1% in pigs, while it reached 75% 
in warthogs. Approximately 33% of pigs and 
78% of warthogs showed antibodies against 
salivary antigens of ticks.  
Prospective cross sectional survey of 
domestic pigs and warthogs were sampled 
to determine the prevalence of antibodies 
against ASF virus and the salivary antigens 
of Ornithodoros spp. ticks, while ticks 
collected from pig pens were tested for 
the presence of ASFV. 
2006-2007 Quembo et al., 2014 
Rwanda 
    
Senegal  Of 747 serum samples examined, 126 were 
positive for ASF, suggesting a prevalence of 
16.9%.  
Seroprevalence survey of ASF in Senegal in 
2006, from a sample of pigs in the 3 main 
pig-farming regions using an ELISA. 
2006 Etter et al., 2011 
South Africa Of 98 warthog burrows inspected for 
Ornithodoros presence, 59 (60.2 %) were 
found to contain tampans and tick sampling 
was significantly male biased.  
Prospective virus surveys targeted at adult 
Ornithodoros ticks: a re-evaluation of 
Mkuze Game reserve, South Africa using 
PCR based virus detection method, 
developed specifically for the sylvatic 
tampan host 
2002 Arnot et al, 2009 [28] 
Tanzania 
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Uganda Prevalence of ASFV in slaughter pigs was 
52.96% (95% CI, 48.75-57.14) and 11.5% 
(95% CI, 9.06-14.45) by ELISA and PCR 
respectively. In surveillance districts, the 
proportion of ASFV positive pigs was 53.59% 
(95% CI, 46.33-60.71) and 0.55% (95% CI, 
0.1-3.06) by ELISA and PCR respectively. 
Cross-sectional seroprevalence and virus 
prevalence of ASFV in apparently healthy 
slaughter pigs at Wambizi slaughterhouse 
in Kampala city, Uganda. We also 
estimated the presence of ASFV antibodies 
and circulating viral antigens in pigs from 
selected districts of Uganda during 
targeted surveillance. Analysis of 540 and 
181 blood samples collected from 
slaughter pigs and pigs from targeted 
surveillance districts respectively. 
2012-2013 Atuhaire et al. 2013, [29] 
 
The prevalence of ASFV in Rakai was 3.3% 
while the seroprevalence was 2.1%.  
Prospective survey to estimate the 
prevalence of ASFV and the 
seroprevalence in domestic pigs in the 
Rakai district in southern Uganda 
2010 Björnheden, 2011 
 
3.8% (38/997) of the pigs examined had 
clinical signs and post- mortem lesions 
suggestive of ASF. Two of 997 (0.2%) sera 
analysed were positive for ASF antibodies.  
A cross-sectional convenient-random 
sampling strategy was used to examine 
pigs and collect sera from22 
slaughterhouses where individual pigs 
were randomly selected for a detailed 
ante- mortem and post-mortem 
inspections. Sera were also collected for 
laboratory analysis. A total of 997 pigs 
(53.7% male and 46.3% female) were 
examined for lesions suggestive of ASF and 
seropositivity of sera for ASF antibodies. 
The sera were tested using enzyme-linked 
immunosorbent assay (ELISA) and positive 
2008-2009 Muwonge et al., 2012 
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samples were further confirmed with an 
immunoblot assay. 
Zambia The prevalence of infection in 0. moubata 
was between 0-4% in South Luangwa 
National Park and 5-1% in Livingstone Game 
Park 
A survey of the distribution of ASF virus in 
Zambia was carried out by VI from 
Ornithodoros moubata ticks collected 
from animal burrows in National Parks and 
Game Management Areas in northern, 
eastern, central and southern Zambia. ASF 
virus was isolated from ticks in all areas 
examined.  
NA Wilkinson et al., 1988 
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Since the first recorded cases in the 1940’s there has been a general increase in the incidence of ASFV outbreaks 
in Africa.  A 10-year peak period in reporting ASFV is observed between 2002 and 2013 and Rwanda, Malawi and 
Madagascar accounted for over half of the total number of outbreaks.  With the continuing and increasing 
transmission of ASFV to the Caucasus region of Asia and the Russian Federation, prevention of further incursion 
into south and Southeast Asia will be critical in the years to come.  China, South and Southeast Asia account for 
over half of the world’s pig population in a diverse set of production systems.  The introduction of ASFV remains 
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Economic and Social Impacts at Global 







Losses of animals of different species are calculated as Livestock Unit (LSU) losses, using the definitions 
presented in Table 10 [31]:  
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Although Africa has 25 million pigs, a relatively small share of the global pig population, ASF ranks as the fourth 
highest cause of economic loss among pig diseases globally [31].  Figure 12 presents a summary of the ranking of 





Figure 12: Ranking of the top 10 pig diseases in terms of Livestock Units lost, 2006-2009 
 
Figure 13 summarizes the geographic distribution of the top 10 countries impacted through LSU losses due to 
ASFV, 2006-2009. In descending order Rwanda, Malawi, Burkina Faso and Mozambique rank among the most 
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Figure 13: Geographic distribution of the top 10 countries impacted through lost LSU due to ASFV, 2006-
2009 
 
Eighty per cent (80%) of pig production in Africa is currently based in smallholder units.  However, Figure 14 
presents the rapid growth of pig production in Africa based on FAOSTAT estimates for 2000-2010 highlighting 
the potential future impact of ASFV [20]. 
 
 
Figure 14: Percentage growth of the pig production sector 2000-2010 
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One study in the U.S. assessed the cost of maintaining a pig population stricken with ASF over a ten-year period 
at US$5.4 billion, with the bulk of this being consumer losses [32].  In Spain, the final 5 years of the eradication 
programme alone were estimated to have cost US$92 million [13].  Estimated economic losses in the Russian 
Federation in 2009 alone were US$1 billion, with 48,000 pig deaths based on OIE data [33].  
Thus far, the greatest impact of ASFV has been on the poorer pig producers lacking basic biosecurity as well as 
the financial resources to restart production in the absence of compensation schemes [13].  The future cost to 
intensive pig production systems in Africa will also be significant.  Using a model 122-sow piggery unit in West 
and Central Africa, a financial model and costing were used to estimate the economic benefits of effective 
biosecurity against ASF. This size of pig production can generate a profit of approximately US$109,637.40 per 
annum and an outbreak of ASF has the potential to cause losses of up to US$910,836.70 in a single year. The 
benefit-cost ratio for implementing biosecurity measures is estimated at 29 [34]. 
Implications of ASFV for food security in Africa are also significant.  Pig production is an important source of 
human dietary protein in many countries, particularly in areas where beef production is difficult. Pigs very 
efficiently convert food waste and agricultural by-products into high quality protein and they have a relatively 
short production cycle [13]. Indirect losses are more difficult to estimate and include the loss of international 
trade and the cost of control measures including culling, government action and loss of production pending 
release of quarantines.  Figure 15 illustrates the trend of live pig sales in smallholder pig units in Rombo district 
of Kilimanjaro, Tanzania as a result of an ASFV outbreak in 2011 [35]. 
 
 
Figure 15: Trend of live pig sales in smallholder pig units in Rombo district of Kilimanjaro, Tanzania 
 
The authors explain that the drop in 2011-2012 is related to ASF outbreaks but do not discuss the reasons for 
the previous drop from 2007-2010 which appear to be more gradual and may possibly be linked to other value 
chain dynamics. Table 11 presents a summary the socioeconomic impacts identified for some of the selected 
African countries where ASFV impact studies have been conducted
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Table 11:  Prevalence estimates of ASFV in selected African countries 
 
Region/Country Economic Impact Social Impact Year Reference 
Sub Saharan Africa 
    
Burkina Faso 
    
Ethiopia 
    
Ivory Coast  Lack financial resources to 
restart production in the 
absence of compensation 
schemes; Loss of between 30 
and 50 per cent of the pig 
population 
The greatest losses are 
usually inflicted on the 
poorer pig producers who 
are less likely to implement 
effective prevention and 
control strategies or basic 
biosecurity. 
1988-1989; 2000 Edelsten & Chinombo 1995; 
El Hicheri et al. 1998; Roger 
et al. 2001 
Kenya 
    
Madagascar Loss of between 30 and 50 
per cent of the pig 
population 
 
2000 El Hicheri et al. 1998; Roger 
et al. 2001 
Malawi 
    
Mali 
    
Mozambique 
    
Rwanda 
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South Africa 
    
Tanzania The impact of an ASF 
outbreak in smallholder pig 
units in Rombo district of 
Kilimanjaro, Tanzania was 
US$75.7 million based on a 
study of 1,085 smallholder 
farmers  
 
2013 Swai and Lyimo, 2014 
Uganda 
    
Zambia Following the 2011 outbreak 
in Isoka district of Zambia: 
50.0% reduction in pig 
population in the surveyed 
area. This ASF outbreak 
caused 99.9% mortality of 
affected pigs. The socio-
economic impacts of the 
disease were in terms of loss 
of the pigs due to 
mortalities, loss of business 
and the cost of disease 
control 
 
2011 Komba et al., 2012 
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Since there is no treatment or vaccine for ASFV, prevention remains the most important means of mitigating the 
risk of ASFV in pig populations and to reduce the economical losses.  FAO has compiled a comprehensive 





No therapeutic control agent for ASFV currently exists. 
 
Sanitary Control Methods 
Since there is no treatment or therapeutic measure available for ASFV, the following interventions have proven 
to be effective [6][20][36]: 
• Rapid disease reporting and zero-reporting at district level; 
• Aggressive active surveillance through “case finding”; 
• ASFV-recovered carrier swine and persistently infected wild pigs require special consideration in 
controlling the disease;  
• Apply basic components of biosecurity:  isolation; movement controls; cleaning and disinfection; and 
carcass removal; 
• Culling affected animals as defined by presumptive (in contact) and confirmed case definitions; 
• Early detection through surveillance and strong two-way linking of trained field epidemiologists and 
laboratory staff; 
• Enabling legislation to control through movement restrictions and humane culling; 
• Zoning to define the infected zone, the surveillance zone and the free zone; 
• Diligent inspection and quarantine services; 
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• Epidemiological surveillance; 
• Humane culling and safe burial; 
• Keep affected premises free of pigs and ticks following culling and burial; 
• Public awareness campaign; 
• Compensation; 
• Social support and rehabilitation; 






An effective vaccine for ASFV is not currently available. 
 
Sanitary Measures: 
In order to prevent ASF, the following measures are recommended [6][27][36][37]): 
 
• Free countries: 
o Careful import policy for animals and animal products;  
o Proper disposal of waste food from vehicles,  aircraft or ships coming from infected 
countries;  
o Efficient sterilization of garbage;  
• Establish effective border and import quarantine policies and pig production best practices; 
• Risk analyses for ASF should provide estimates of the following: 
o Release assessment; 
o Exposure assessment; 
o Consequence assessment; 
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• Conduct value chain and social network analysis of pig production; 
• Epidemiological surveillance based on risk assessments; 
• Education to develop informed animal owners;  
• Place a ban on swill feeding or implementing controls (cooking) that will make it safe;  
• Education and training on improving basic components of biosecurity:  isolation; movement 
controls; cleaning and disinfection; and carcass removal; 
• Capacity development and strengthening of laboratories; 
• Define pig production compartments to prevent transmission among them. 
 
Options and Strategies for Vaccination 
There is currently no safe and effective vaccine for the prevention and control of ASFV.  However, the 
eradication of ASF from Portugal and Spain, after more than 20 years of endemicity, proved that vaccine is not 
essential in the eradication of this complex disease [4].  The following strategy is recommended for proceeding 
with the development of an effective vaccine for ASFV based on published literature and consultation with 
experts: 
1. Address the need to conduct basic science to better understand ASFV.  Contribute to a long-term, 
coordinated and systematic analysis of families of antigens and as well as a systematic study of the 
innate and acquired immune mechanisms of the ASFV.  This could be accomplished through facilitating 
an international network of excellence for antigenic and immune related research. 
2. Leverage efforts of research institutions through partnerships with the vaccine industry from the initial 
stages to develop commercial products. 
3. Develop appropriate vaccine models, which can be transferred to private vaccine companies to support 
a multivalent delivery platform. 
4. Develop rapid pen side test for ASFV to support rapid diagnosis that permits differentiating infected 
from vaccinated animals (DIVA). 
5. Develop novel laboratory based cell lines to replace the current reliance on pig macrophage and bone 
cells, which is cumbersome and can result in variable results. 
 
Government policies related to prevention and control of ASF are presented in Table 12. 
African Swine Fever | Monograph 08 






Table 12: Official prevention and control policies for ASFV among the 20 selected countries. 
 







(yes/no) (yes/no) (yes/no) 
Country 
   
Compulsory 
vaccination 

























         
Ethiopia 
         
Ivory Coast Yes Passif mais actif 
en cas d’epizootie 
Yes No 
   
No 
 
Kenya Yes Yes, passive No N/A N/A N/A N/A Yes No 
Madagascar 
         
Malawi Yes Yes (passive) Yes N/A N/A N/A N/A N/A N/A 
Mali 
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Rwanda Yes Both Yes No No No Pigs No No 
Senegal 
         
South Africa 
         




N/A N/A N/A N/A No No 
Uganda Yes No No (No 
vaccines) 




         
Bangladesh No No No No No No No No No 
India 
         
Nepal No No No No N/A N/A N/A N/A N/A 
Indonesia 
         
Myanmar No Yes (passive) No No - - - No No 
Vietnam No No No No - - - - - 
 
1Surveillance: is the systematic on going collection, collation and analysis of data and the timely dissemination of information to those who need to know so that 
action can be taken.  
2Control: a programme which is approved, and managed or supervised by the Veterinary Authority of a country for the purpose of controlling a vector, pathogen 
or disease by specific measures applied throughout that country, or within a zone or compartment of that country 
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The first attempt to develop a vaccine took place in 1963 in Portugal but an effective vaccine has not yet been 
developed. Live-attenuated, inactivated, proteins or recombinant vaccines have been tried unsuccessfully. The 
reasons for failure include the fact that the ASFV do not induce neutralizing antibodies and the ASFV are highly 
variable genetically due to homologous reassortment of the MGF [4].  In addition, it has been demonstrated that 
mainly CD8 T cells of multiple antigenic specificities are activated after ASFV infection in pigs explaining why 
immunization using only one epitope has failed [4].  
 
The following avenues for vaccine research have been pursued: 
• Inactivated Vaccine does not produce any protection based on antibody production and challenge 
studies [4].  
• Recombinant Baculovirus-based Vector, BacMam-sHAPQ expressing a fusion protein as well as ASFV 
antigens p54, p30 and the extracellular domain of the viral haemagglutinin has been developed. The, 
BacMam-sHAPQ vaccine induced specific T-cell responses directly after in vivo immunization. However, 
no specific antibody responses were detectable prior to ASFV challenge [38].  
• Subunit Vaccine from Spain is currently being developed (Fernando Rodriguez, Centre de Recerca en 
Sanitat Animal (CReSA), UAB-IRTA, Campus de la UAB, 08193 Bellaterra, Barcelona, Spain. 
• Live-attenuated Vaccine (by passages in cultured Vero cells) protects some pigs against challenge with 
the homologous strain of virus, but the possibility of some of these pigs becoming carriers and 
developing chronic lesions exists increases when a large number of pigs are vaccinated. Other studies 
have shown that serum from pigs resistant to homologous and some heterologous strains of ASFV 
inhibit (in vitro) infection of cells with different, but related, heterologous strains [4].  
• Recombinant Vector Vaccines using Aujezsky’s disease virus and Adenovirus targeting innate and 
acquired immune mechanisms (humoral and cell mediated) [4][39].  
• Recombinant Proteins of the Same Virus Antigens and Including a Fragment of an Antibody delivery 
recognizing porcine major histocompatibility complex (MHC) class 2 to pig antigen presenting cells [4].  
• Gene Deleted (attenuated) Recombinant vaccine specifically for genes of virulence and immune system 
evasion or deficient to replicates in cells [4].  
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The ASFV genome has between 150 and 165 genes.  Table 13 provides a summary of some important ASFV 
candidate genes considered for use in the vaccine models noted above [4][39]:  
 
Products available in 20 selected countries and doses used:  
None. 
 
Commercial vaccines manufactured in Africa and Asia 
None. 
 
Commercial vaccines imported into Africa and Asia 
None. 
Table 13: ASFV candidate genes considered for use in the vaccine models 
 
ASF Genes Role References 
CD2v Adhesion protein that mediate the haemadsorbtion on red blood cells 
accelerating virus propagation in pigs, delaying the onset of the disease 
Borca et al., 1998 
A238L Modulation of the immune response by interfering with the induction of 
pro-inflammatory cytokines; inhibiting the NFAT transcription factor 
controlling the activation of lymphocytes 
Tait et al., 2000; 
Miskin, 1998 and 
2000 
j4R A virus–encoded ubiquitin conjugating enzyme having a role in the 
modulating the host gene transcription pathway 
Goatley et al., 2002; 
Bulimo et al., 2000 
genes belonging 
to the MGF 
Virus virulence Tulman and Rock, 
2001 
p54 and p72 Prevent virus attachment [4] 
p30 Inhibits virus internalization [4] 
D117 and 
EP152R 
Expressed early in infection and are associated with IL (IL8, IL12, IL1a, IL4) 
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Target product profile 
 
Attribute Minimum (currently 
available vaccine) 
Ideal 
Antigen Not applicable Select based on systematic review of all ASFV antigens 
Indication for use Not applicable Prevent and control ASFV replication and shedding 
Recommended species Not applicable Domestic Pig 
Recommended dose Not applicable To be determined – initial: 0.5 ml; booster ideally 1-2 ml 
Pharmaceutical form Not applicable Options: Inactivated non-replicating recombinant (gene 
deleted) with DIVA capability or replicating vector based 
delivery 
Route of administration Not applicable Intramuscular 
Regimen – primary 
vaccination 
Not applicable To be determined – ideally 45 days of age  
Regimen – booster Not applicable To be determined – ideally every 6 months 
Epidemiological relevance and 
use for smallholders 
Not applicable Ideally cross-protective across genotypes  
Recommended age at first 
vaccination 
Not applicable With no maternal immunity - Ideally by 45 days of age 
Onset of immunity Not applicable 7-10 days post vaccination 
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Key Conclusions Related to Vaccination 
The key challenges to developing a safe and effective vaccine for ASFV include, lack of understanding of the 
agent-host relationship including: 
• Mechanism of immune system evasion for ASFV both innate i.e. macrophages and monocytes and 
acquired immune systems including both humoral and cell-associated aspects; 
• Inability of the pig host to develop neutralizing antibodies to ASFV; 
• Differences among the 22 known genotypes; 
• Antigenicity of the approximately 150-165 genes of ASFV to target the development of a safe and 
effective vaccine;  
• Dynamics of undergoing internal re-assortment and presence of MGF which impedes the ability to 
develop an effective and safe vaccine; 
• Coordination of basic research among international experts; 
• A model for both knowledge generation and technology transfer to vaccine developers for commercial 
vaccine production; 
• Regional- and country-specific vaccination strategies to deal with the unique epidemiological drivers of 
ASFV of each area. 
Duration of immunity Not applicable Ideally 6 months 
Expected efficacy Not applicable 90-100% 
Expected safety Not applicable 100% 
Withdrawal period Not applicable Ideally 21-42 days 
Special requirements for 
animals 
Not applicable No possibility of reversion to virulent form or tissue 
granulomas; multivalent formulation with other priority 
pig diseases 
Special requirements for 
persons 
Not applicable No tissue granulomas and no possibility of anaphylaxis 
Package size Not applicable 20 doses for smallholders up to 100 doses 
Price to end user Not applicable Similar to costs for Aujesky’s disease*  
Storage condition and shelf-
life as packages for sale 
Not applicable Keep frozen*  
In-use stability Not applicable 18 months* 
* Based on gene deleted vaccine for Aujesky’s Disease 
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There is very limited country level information available concerning the epidemiology and socioeconomic impact 
of ASFV with the exception of Mozambique and Uganda.  Reporting bias presents a significant handicap for 
estimating country-based risk for A in section 3.  However, the OIE incidence country estimates are 
complemented by AU-IBAR for at least one year.  It is evident from a review of the literature that communities 
in Africa have become accustomed to dealing with ASFV.  Community engagement and understanding the 
knowledge, attitudes and practices (KAP) at the local level in relation to ASFV will therefore a critical 
consideration for any future vaccination initiative and AusAID is supporting such social science research. 
Several international experts were not available or did not respond to requests for an interview. 
 
Gaps in knowledge or capacity impacting strategic planning and effective implementation of a vaccination 
program for ASFV 
A replicating vector vaccine model holds the promise of on going immune stimulation from the vector virus 
however for wider eventual acceptance a non-replicating, gene deleted vaccine model may be preferred due to 
lack of environmental concerns and both approaches are being taken internationally at this time.  This should be 
considered as a potential limiting factor. 
The development of safe and effective vaccines for ASFV may be 10 years ahead due to the limited amount of 
basic research, which has been conducted to date.  Culling remains an effective means of eradicating ASFV from 
European countries over prolonged campaigns.  Reliance on humane culling used successful in Europe to control 
ASFV, is not possible due to food security and technical and financial constraints evident in developing countries.  
Nor is sufficient epidemiological and laboratory capacity available to rapidly detect and diagnose the disease.  
The key gaps and solutions that need to be addressed prior to developing a potential vaccine are as follows: 
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• Facilitating coordination among international researchers to advance knowledge of the basic science of 
ASFV through a systematic approach for antigenic and immune related research; 
• Building local capacity for rapid detection including the development of a rapid pen side test for ASFV to 
support rapid diagnosis and permits differentiating infected from vaccinated animals (DIVA); 
• Conducting epidemiological and socioeconomic studies at the country and transboundary levels to 
understand the drivers and impacts of ASFV, including introduction, transmission and endemicity; 
• Leveraging efforts of research institutions through partnerships with the vaccine industry from the initial 
stages with potential to develop commercial products.  
Medium term 
• Study infection dynamics based on direct challenge and indirect contact from infected animals; 
• Develop vaccine discovery models based on evidence from antigenic and immunological studies;  
• Promoting technology transfer to private vaccine companies to support a multivalent delivery platform. 
Long term 
• Developing vaccines and vaccine delivery systems appropriate for each country and region based on 
molecular, epidemiological and socioeconomic parameters. 
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